Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Abstract AIMS: Hyperphosphatemia has been associated with an increased risk of mortality in patients with end-stage renal disease. We
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
Abstract Background Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphataemia in adult dialysis
הטיפול ב- Sucroferric (וולפורו) אינו נחות מ-sevelamer (רנוולה) בשליטה ברמות הזרחן במטופלים בדיאליזה פריטוניאלית וזאת בלווי נטל תרופתי קטן יותר והיענות גבוהה יותר (Nephrol Dial Transplant )
ע"פ מחקר חדש מה-Nephrol Dial Transplant הטיפול ב-Sucroferric oxyhydroxide (וולפורו) אינו נחות מהטיפול ב-sevelamer(רנוולה) לשליטה ברמות הזרחן במטופלים בדיאליזה פריטוניאלית (PD)
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients
Abstract BACKGROUND: Many patients with chronic kidney disease are prescribed vitamin D receptor agonists (VDRAs) for the management of secondary hyperparathyroidism. Oral phosphate binders may
Phosphate binders in chronic kidney disease: a systematic review of recent data
Abstract Hyperphosphatemia is common in chronic kidney disease (CKD) and is treated by dietary measures, dialysis techniques and/or phosphatebinders. For the present
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study
Abstract BACKGROUND: Abnormalities in serum phosphorus, calcium and parathyroid hormone (PTH) have been associated with poor survival in haemodialysis patients. This COSMOS (Current management Of Secondary hyperparathyroidism:
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
Abstract Background Hyperphosphatemia necessitates the use of phosphate binders in most dialysis patients. Long-term efficacy and tolerability of the
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
Abstract Sucroferric oxyhydroxide (VELPHORO) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
Abstract Efficacy of PA21 (sucroferric oxyhydroxide), a novel calcium-free polynuclear iron(III)-oxyhydroxide phosphate binder, was compared with that of sevelamer carbonate in
The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro
Abstract AIMS: Hyperphosphatemia in advanced chronic kidney disease (CKD) necessitates the use of phosphate binders. This in vitro study assessed phosphate binding and Fe release properties of the
PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease
Abstract AIM: Limitations of conventional phosphate binders have led to the development of novel non-calcium, non-aluminium agents for use in patients with chronic kidney
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
Abstract AIMS: Hyperphosphatemia has been associated with an increased risk of mortality in patients with end-stage renal disease. We sought to assess the
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
Abstract Background Sucroferric oxyhydroxide is a non-calcium, iron-based
הטיפול ב- Sucroferric (וולפורו) אינו נחות מ-sevelamer (רנוולה) בשליטה ברמות הזרחן במטופלים בדיאליזה פריטוניאלית וזאת בלווי נטל תרופתי קטן יותר והיענות גבוהה יותר (Nephrol Dial Transplant )
ע"פ מחקר חדש מה-Nephrol Dial Transplant הטיפול ב-Sucroferric oxyhydroxide
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients
Abstract BACKGROUND: Many patients with chronic kidney disease are prescribed vitamin D receptor agonists
Phosphate binders in chronic kidney disease: a systematic review of recent data
Abstract Hyperphosphatemia is common in chronic kidney disease
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study
Abstract BACKGROUND: Abnormalities in serum phosphorus, calcium and
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
Abstract Background Hyperphosphatemia necessitates the use of phosphate
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide
Abstract Sucroferric oxyhydroxide (VELPHORO) is a polynuclear iron-based
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
Abstract Efficacy of PA21 (sucroferric oxyhydroxide), a novel
The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro
Abstract AIMS: Hyperphosphatemia in advanced chronic kidney disease
PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease
Abstract AIM: Limitations of conventional phosphate binders have led to